$5.5M Financing Fuels NEXGEL's Celularity Segment Acquisition, Expected to Triple Revenue
NXGL sits 20% above its 52-week low of $0.56 on light trading volume (0.4× avg).
Summary
NEXGEL Inc. has completed the acquisition of Celularity Inc.'s degenerative disease segment, a move expected to significantly transform the company. The transaction is financed by a $5.5 million strategic investment from new partner Sequence LifeScience™. This acquisition is projected to approximately triple NEXGEL's annual revenue to $35 million and be immediately accretive to profitability, establishing a new BioNX Surgical division focused on regenerative medicine. This event aligns with Celularity's recent 8-K filing regarding an asset sale, indicating a strategic divestiture for them. Traders should monitor the integration of the acquired assets, the expansion of distribution channels, and the progress of planned 510(k) filings for new products. The company is hosting a shareholder update call today for further details.
At the time of this announcement, NXGL was trading at $0.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1M. The 52-week trading range was $0.56 to $2.99. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.